Active substance
Fenofibrate
- SFDA 14
- US FDA 59
- Health Canada 10
- US price lines 13
- Safety 6
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| FENOGAL 200MG LIDOSE CAPSULES | 200 mg | Capsule, hard · Oral use | 30 Blister | SAR 31.50 | NCE · Prescription | S.M.B. | Valid |
| Fenofibrate Ethypharm | 145 mg | Tablet · Oral use | 30 Blister | SAR 37.85 | Generic · Prescription | Macarthys Laboratories Ltd t/a Martindale Pharma | Valid |
| Finate | 200 mg | Capsule, hard · Oral use | 30 Blister | SAR 37.85 | Generic · Prescription | Jamjoom Pharmaceuticals Factory Company | Valid |
| LIPANTHYL 145MG F.C. TABLETS | 145 mg | Film-coated tablet · Oral use | 30 Blister | SAR 44.55 | NCE · Prescription | Abbott Laboratories GmbH | Valid |
| LIPANTHYL 200MG MICRONISED CAPS | 200 mg | Capsule, hard · Oral use | 30 Blister | SAR 44.55 | NCE · Prescription | Abbott Laboratories | Valid |
| LYPFEN | 200 mg | Capsule, hard · Oral use | 30 Blister | SAR 35.95 | Generic · Prescription | ALPHA PHARMA INDUSTRY | Valid |
| Lipofirate | 145 mg | Film-coated tablet · Oral use | 30 Blister | SAR 37.85 | Generic · Prescription | Saudi Amarox | Valid |
| Lipofirate | 48 mg | Film-coated tablet · Oral use | 30 Blister | SAR 12.50 | Generic · Prescription | Saudi Amarox | Valid |
| Lipofirate | 145 mg | Film-coated tablet · Oral use | 60 Blister | SAR 75.70 | Generic · Prescription | Saudi Amarox | Valid |
| Lipofirate | 48 mg | Film-coated tablet · Oral use | 60 Blister | SAR 25.00 | Generic · Prescription | Saudi Amarox | Valid |
| TRIX 200 mg Capsule | 200 mg | Capsule · Oral use | 30 Blister | SAR 31.55 | Generic · Prescription | Jordan Sweden Medical and Sterilization Co. | Valid |
| LIPANTHYL 145MG F.C. TABLETS | 145 mg | Film-coated tablet · Oral use | 30 Blister | SAR 44.55 | NCE · Prescription | RECIPHARMA | Withdrawn by MAH · Not Marketed |
| LIPANTHYL 200MG MICRONISED CAPS | 200 mg | Capsule, hard · Oral use | 30 Blister | SAR 44.55 | NCE · Prescription | RECIPHARMA | Withdrawn by MAH · Not Marketed |
| LIPANTHYL 200MG MICRONISED CAPS | 200 mg | Capsule, hard · Oral use | 30 Blister | SAR 44.55 | NCE · Prescription | Abbvie Limited | Withdrawn by MAH · Not Marketed |
Indications — CHI Daman Drug Formulary
DYSLIPIDEMIA; PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| ANTARA (MICRONIZED) | 43MG; 130MG | capsule · oral | LUPIN | Prescription | 30 Nov 2004 |
| FENOFIBRATE | 54MG; 160MG | tablet · oral | RHODES PHARMS | Prescription | 13 May 2005 |
| FENOFIBRATE | 107MG | tablet · oral | SUN PHARM INDS LTD | Prescription | 31 Oct 2005 |
| LIPOFEN | 50MG; 150MG | capsule · oral | CIPHER PHARMS INC | Prescription | 11 Jan 2006 |
| FENOFIBRATE | 54MG; 160MG | tablet · oral | IMPAX LABS | Prescription | 26 Mar 2008 |
| FENOFIBRATE | 48MG; 145MG | tablet · oral | LUPIN LTD | Prescription | 23 Dec 2011 |
| FENOFIBRATE (MICRONIZED) | 43MG; 130MG | capsule · oral | CHARTWELL RX | Prescription | 1 Mar 2012 |
| FENOFIBRATE | 48MG; 145MG | tablet · oral | MYLAN PHARMS INC | Prescription | 7 Dec 2012 |
| FENOFIBRATE (MICRONIZED) | 43MG; 130MG | capsule · oral | APOTEX | Prescription | 26 Jul 2013 |
| FENOFIBRATE | 54MG; 160MG | tablet · oral | LUPIN | Prescription | 17 Aug 2015 |
| FENOFIBRATE | 48MG; 145MG | tablet · oral | AUROBINDO PHARMA | Prescription | 5 May 2016 |
| FENOFIBRATE | 40MG; 120MG | tablet · oral | MYLAN PHARMS INC | Prescription | 23 Jun 2016 |
| FENOFIBRATE | 48MG; 145MG | tablet · oral | HETERO LABS LTD III | Prescription | 12 Jul 2016 |
| FENOFIBRATE | 48MG; 145MG | tablet · oral | CIPLA | Prescription | 15 Dec 2016 |
| FENOFIBRATE (MICRONIZED) | 67MG; 134MG; 200MG | capsule · oral | GLENMARK PHARMS LTD | Prescription | 7 Apr 2017 |
| FENOFIBRATE (MICRONIZED) | 67MG; 134MG; 200MG | capsule · oral | REYOUNG | Prescription | 16 Nov 2017 |
| FENOFIBRATE | 54MG; 160MG | tablet · oral | BOSTAL | Prescription | 19 Dec 2017 |
| FENOFIBRATE | 48MG; 145MG | tablet · oral | AMNEAL | Prescription | 9 Feb 2018 |
| FENOFIBRATE | 54MG; 160MG | tablet · oral | AMNEAL | Prescription | 19 Mar 2018 |
| FENOFIBRATE (MICRONIZED) | 67MG; 134MG; 200MG | capsule · oral | ANI PHARMS | Prescription | 30 Apr 2018 |
| FENOFIBRATE (MICRONIZED) | 67MG; 134MG; 200MG | capsule · oral | TORRENT | Prescription | 26 Jun 2018 |
| FENOFIBRATE | 54MG; 160MG | tablet · oral | AJANTA PHARMA LTD | Prescription | 20 Jul 2018 |
| FENOFIBRATE | 54MG; 160MG | tablet · oral | RISING | Prescription | 17 Aug 2018 |
| FENOFIBRATE | 48MG; 145MG | tablet · oral | PRINSTON INC | Prescription | 28 Aug 2018 |
| FENOFIBRATE (MICRONIZED) | 67MG; 134MG; 200MG | capsule · oral | AJANTA PHARMA LTD | Prescription | 10 Sep 2018 |
34 more — full table
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| AA-FENO-MICRO | 02239864 | 200 MG | CAPSULE · ORAL | AA PHARMA INC |
| AA-FENO-MICRO | 02243180 | 67 MG | CAPSULE · ORAL | AA PHARMA INC |
| AA-FENO-SUPER | 02246859 | 100 MG | TABLET · ORAL | AA PHARMA INC |
| AA-FENO-SUPER | 02246860 | 160 MG | TABLET · ORAL | AA PHARMA INC |
| LIPIDIL EZ | 02269074 | 48 MG | TABLET · ORAL | BGP PHARMA ULC |
| LIPIDIL EZ | 02269082 | 145 MG | TABLET · ORAL | BGP PHARMA ULC |
| LIPIDIL SUPRA | 02241602 | 160 MG | TABLET · ORAL | BGP PHARMA ULC |
| SANDOZ FENOFIBRATE E | 02390698 | 48.0 MG | TABLET · ORAL | SANDOZ CANADA INCORPORATED |
| SANDOZ FENOFIBRATE E | 02390701 | 145.0 MG | TABLET · ORAL | SANDOZ CANADA INCORPORATED |
| SPC-FENOFIBRATE E | 02454696 | 145 MG | TABLET · ORAL | SUN PHARMA CANADA INC |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | FENOFIBRATE 120 MG TABLET | $16.75499 | per EA | 23 Sep 2026 |
| US NADAC | FENOFIBRATE 130 MG CAPSULE | $0.70221 | per EA | 23 Sep 2026 |
| US NADAC | FENOFIBRATE 134 MG CAPSULE | $0.11925 | per EA | 23 Sep 2026 |
| US NADAC | FENOFIBRATE 145 MG TABLET | $0.11959 | per EA | 23 Sep 2026 |
| US NADAC | FENOFIBRATE 150 MG CAPSULE | $5.30292 | per EA | 23 Sep 2026 |
| US NADAC | FENOFIBRATE 160 MG TABLET | $0.1033 | per EA | 23 Sep 2026 |
| US NADAC | FENOFIBRATE 200 MG CAPSULE | $0.16437 | per EA | 23 Sep 2026 |
| US NADAC | FENOFIBRATE 40 MG TABLET | $5.53539 | per EA | 23 Sep 2026 |
| US NADAC | FENOFIBRATE 43 MG CAPSULE | $0.38364 | per EA | 23 Sep 2026 |
| US NADAC | FENOFIBRATE 48 MG TABLET | $0.07936 | per EA | 23 Sep 2026 |
| US NADAC | FENOFIBRATE 50 MG CAPSULE | $2.55969 | per EA | 23 Sep 2026 |
| US NADAC | FENOFIBRATE 54 MG TABLET | $0.07335 | per EA | 23 Sep 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Safety signals and safety-related labeling changes
- US FDA 1 Oct 2025 ANTARA (MICRONIZED) — safety-related labeling change
Labeling sections changed: Contraindications; Warnings and Precautions; Adverse Reactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 6 Jun 2025 FENOGLIDE — safety-related labeling change
Labeling sections changed: Contraindications; Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 6 Jun 2025 LIPOFEN — safety-related labeling change
Labeling sections changed: Contraindications; Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 6 Jun 2025 TRICOR — safety-related labeling change
Labeling sections changed: Contraindications; Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 14 May 2024 TRIGLIDE — safety-related labeling change
Labeling sections changed: Contraindications; Warnings and Precautions; Adverse Reactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 28 Mar 2019 TRICOR — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide
Combinations containing Fenofibrate
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.